Cerinib 150 mg (Ceritinib)


Cerinib 150 mg (Ceritinib)

Introduction to Cerinib 150 mg (Ceritinib)

Cerinib 150 mg, meticulously crafted by Drug International Limited and distributed by Orio Pharma, represents a significant advancement in the treatment of ALK-positive non-small cell lung cancer (NSCLC). Ceritinib, the active ingredient in Cerinib, offers a targeted approach, providing hope and improved outcomes for individuals battling this specific type of lung cancer.

Description: Cerinib 150 mg (Ceritinib)

Cerinib 150 mg utilizes Ceritinib, an anaplastic lymphoma kinase (ALK) inhibitor. This medication specifically targets and inhibits the activity of the ALK protein, which is involved in the growth and spread of cancer cells in ALK-positive NSCLC patients.

Mechanism of Action

Ceritinib works by selectively inhibiting the ALK protein, which is often abnormally expressed in certain types of cancer. By blocking this protein’s activity, Cerinib 150 mg prevents the proliferation and spread of cancer cells, offering a targeted and effective treatment for ALK-positive NSCLC.

Clinical Use

Cerinib 150 mg is primarily prescribed for:

  • ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Recommended for the treatment of ALK-positive, advanced, or metastatic NSCLC in patients who have progressed on or are intolerant to other ALK inhibitors.

Dosage and Administration

Healthcare professionals determine the dosage of Cerinib 150 mg based on the specific characteristics of the patient and the treatment plan. Administered orally, the treatment involves a specific schedule of daily doses. It is important to follow the prescribed regimen to achieve optimal results.

Benefits of Cerinib 150 mg (Ceritinib)

  • Targeted Therapy: Cerinib’s specific inhibition of the ALK protein provides a precise approach to treating ALK-positive NSCLC, improving patient outcomes.
  • Enhanced Progression-Free Survival: Ceritinib has demonstrated significant improvements in progression-free survival, offering patients longer periods without disease progression.
  • Quality of Life: By targeting the root cause of ALK-positive NSCLC, Cerinib helps manage symptoms and improve the overall quality of life for patients.

Manufacturer: Drug International Limited

Drug International Limited, the esteemed manufacturer of Cerinib 150 mg, is dedicated to producing pharmaceuticals of the highest quality. Their commitment to innovation and stringent quality control ensures that Cerinib 150 mg meets the highest standards of efficacy and safety.

Supplier: Orio Pharma

Orio Pharma, the trusted distributor of Cerinib 150 mg, ensures that this essential medication is accessible to healthcare providers and patients worldwide. Their dedication to excellence in distribution guarantees timely and reliable access to Cerinib.


In conclusion, Cerinib 150 mg (Ceritinib) is a groundbreaking medication for the treatment of ALK-positive non-small cell lung cancer. Manufactured by Drug International Limited and supplied by Orio Pharma, this treatment offers a targeted and effective approach to cancer therapy.

The precision of Ceritinib in inhibiting the ALK protein underscores its role as a potent and well-tolerated therapeutic option. The collaboration between Drug International Limited and Orio Pharma ensures the highest standards of manufacturing and distribution, making Cerinib 150 mg a reliable and accessible option for patients striving for better health outcomes in their battle against ALK-positive NSCLC.